CD274 and metastatic melanoma: As assessed by SP142, Tang et al18 reported that patients with PD-L1 expression of at least 50% have the most favorable objective response rate (ORR) and disease control rate (DCR) as well as superior overall survival (OS) in metastatic melanoma and urological cancers.18 Similarly, Wang et al19 demonstrated that patients with PD-L1 expression of at least 1% have significantly better ORR and DCR in advanced gastric cancer.19 JS311 is a novel PD-L1 IHC antibody staining mainly membrane and cytoplasma, which was developed specifically to guide the application of toripalimab.